ONLINE SUPPLEMENT
Magnitude of blood pressure reduction in the placebo arms of modern hypertension
trials: Implications for trials of renal denervation
Hitesh C Patel,1,2,* Carl Hayward,1,2,* Baris Ata Ozdemir,3 Stuart D Rosen,2,4 Henry Krum,5
Alexander R Lyon,1,2 Darrel P Francis,2 Carlo di Mario1,2
1
NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK
National Heart and Lung Institute, Imperial College, London, UK
3
Department of Outcomes Research, St. George’s Vascular Institute, St George’s University,
London, UK
4
Department of Cardiology, Ealing Hospital NHS Trust, Southall, London, UK
5
Monash Centre of Cardiovascular Research and Education in Therapeutics, School of
Public Health and Preventive Medicine, Monash University, Alfred Hospital, Melbourne,
VIC, Australia
2
*HP and CH contributed equally to the manuscript
Corresponding Author:
Dr Hitesh Patel, Cardiology Research Fellow
Cardiovascular BRU, Royal Brompton Hospital
London UK, SW3 6NP
Tel: +44 207 352 8121 x2920
Fax: +44 207 351 8184
Email: h.patel3@rbht.nhs.uk
1
S1: Flow chart for study selection. BP= blood pressure
2
S2: Individual characteristics of the 52 non-resistant hypertension and 8 resistant
hypertension trials included in the meta-analysis. SBP=systolic blood pressure;
DBP=diastolic blood pressure; ABPM=ambulatory blood pressure monitoring; NR=no
record.
3
Supplementary references
S1. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe D. Aliskiren, a novel oral renin
inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients
with hypertension. Hypertens Res. 2006;29:997-1005.
S2. Jordan J, Engeli S, Boye S, Le Breton S, Keefe D. Direct renin inhibition with aliskiren in
obese patients with arterial hypertension. Hypertension. 2007;49:1047-1055.
S3. Gradman A, Schmieder R, Lins R, Nussberger J, Chiang Y, Bedigian M. Aliskiren, a
novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and
placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
S4. Geiger H, Barranco E, Gorostidi M, Taylor A, Zhang X, Xiang Z, Zhang J. Combination
therapy with various combination of aliskiren, valsartan, and hydrochlorothiazide in
hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin
Hypertens. 2009;11:324–332.
S5. Puig J, Schunkert H, Taylor A, Boye S, Jin J, Keefe D. Evaluation of the dose-response
relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized,
double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2
essential hypertension. Clin Ther. 2009;31:2839–2850.
S6. Oh BH, Mitchell J, Herron J, Chung J, Khan M, Keefe D. Aliskiren, an oral renin
inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in
patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.
S7. Pool J, Schmieder R, Azizi M, Aldigier JC, Januszewicz A, Zidek W, Chiang Y, Satlin A.
Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in
combination with valsartan. AJH. 2007;20:11-20.
S8. Drummond W, Munger M, Essop M, Maboudian M, Khan M, Keefe D. Antihypertensive
efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not
responding to amlodipine monotherapy. J Clin Hypertens. 2007;9:742-750.
S9. Drummond W, Sirenko Y, Ramos E, Baek I, Keefe D. Aliskiren as add-on therapy in the
treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT
combination. A placebo-controlled study. Am J Cardiovasc Drugs. 2011;11:327-333.
S10. Villa G, Le Breton S, Ibram G, Keefe D. Efficacy, safety, and tolerability of aliskiren
monotherapy administered with a light meal in elderly hypertensive patients: a randomized,
double-blind, placebo-controlled, dose-response evaluation study. J Clin Pharmacol.
2012;52:1901-1911.
S11. Villamill A, Chrysant S, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L,
Zhang J. Renin inhibition with aliskiren provides additive antihypertensive efficacy when
used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217-226.
S12. Littlejohn T, Jones S, Zhang J, Hsu H, Keefe D. Efficacy and safety of aliskiren and
amlodipine combination therapy in patients with hypertension: a randomized, double-blind,
multifactorial study. J Hum Hypertens. 2013;27:321-327.
S13. Schmieder R, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian
M, Botha J, van Ingen H. Circulation. 2009;119:417-425.
S14. Blumenstein M, Romaszkp J, Calderon A, Andersen K, Ibram G, Liu Z, Zhang J.
Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill
combinations in patients who are non-responsive to HCT 25mg alone. Curr Med Res Opin.
2009; 25:903-910.
S15. Glorioso N, Thomas M, Troffa C, Argiolas G, Patel S, Baek I, Zhang J.
Antihypertensive efficacy and tolerability of aliskiren/amlodipine single-pill combinations in
patients with an inadequate response to aliskiren monotherapy. Current Vascular
Pharmacology. 2012;10:748-755.
4
S16. Pfeiffer D, Rennie N, Papst C, Zhang J. Efficacy and tolerability of aliskiren/amlodipine
single-pill combinations in patients who did not respond fully to amlodipine monotherapy.
Current Vascular Pharmacology. 2012;10:773-780.
S17. Nickenig G, Simanenkov V, Lembo G, Rodriguez P, Salko T, Ritter S, Zhang J.
Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren nonresponders. Blood Pressure. 2008;17:31-40.
S18. Oparil S, Yarows S, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined
use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial.
Lancet. 2007;370:221-29.
S19. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/200796Orig1s000MedR.pdf
(11 September 2014).
S20. Bakris G, Sica D, Weber M, White W, Roberts A, Perez A, Cao C, Kupfer S. The
comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood
pressure. J Clin Hypertens. 2011;13:81-88.
S21. White W, Weber M, Sica D, Bakris G, Perez A, Cao C, Kupfer S. Effects of angiotensin
receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and
clinic blood pressure in patients with stages 1 and 2 hypertension. Hypertension.
2011;57:413-420.
S22. Saruta T, Kageyama S, Ogihara T, Hiwada K, Ogawa M, Tawara K, Gatlin M,
Garthwaite S, Bittman R, Patrick J. Efficacy and safety of the selective aldosterone blocker
eplerenone in Japanese patients with hypertension: a randomized, double-blind, placebocontrolled, dose-ranging study. J Clin Hypertens. 2004;6:175-185.
S23. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-437_Inspra_Medr_P3.pdf
(11 September 2014).
S24. Weinberger M, Roniker B, Krause S, Weiss R. Eplerenone, a selective aldosterone
blocker, in mild-to-moderate hypertension. AJH. 2002;15:709-716.
S25. Calhoun D, White W, Krum H, Guo W, Bermann G, Trapani A, Lefkowitz M, Menard
J. Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension:
results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.
Circulation. 2011;124:1945-1955.
S26. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of
eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension.
2002;40:117-123.
S27. White W, Carr A, Krause S, Jordan R, Roniker B, Oigman W. Assessment of the novel
selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in
patients with systemic hypertension. Am J Cardiol. 2003;92:38-42.
S28. Flack J, Oparil S, Pratt H, Roniker B, Garthwaite S, Kleiman J, Yang Y, Krause S,
Workman D, Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive
black and white patients. J Am Coll Cardiol. 2003;41:1148-55.
S29. Chan T, Woo K, Nicholls M. The application of nebivolol in essential hypertension: a
double-blind, randomized, placebo-controlled study. Int J Cardiol. 1992;35:387-395.
S30. Saunders E, Smith W, DeSalvo K, Sullivan W. The efficacy and tolerability of nebivolol
in hypertensive African American patients. J Clin Hypertens. 2007;9:866-875.
S31. Greathouse M. Nebivolol efficacy and safety in patients with stage I-II hypertension.
Clin Cardiol. 2010;33:E20–E27.
S32. Weiss R, Weber M, Carr A, Sullivan W. A randomized, double-blind, placebocontrolled parallel-group study to assess the efficacy and safety of nebivolol, a novel Bblocker, in patients with mild to moderate hypertension. J Clin Hypertens. 2007;9:667-676.
S33. Weber M, Basile J, Stapff M, Khan B, Zhou D. Blood pressure effects of combined Bblocker and angiotensin-converting enzyme inhibitor therapy compared with the individual
5
agents: a placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens.
2012;14:588–592.
S34. Deedwania P, Shea J, Chen W, Brener L. Effects of add-on nebivolol on blood pressure
and glucose parameters in hypertensive patients with prediabetes. J Clin Hypertens.
2013;15:270-278.
S35. Van Nueten L, Taylor F, Robertson J. Nebivolol vs atenolol and placebo in essential
hypertension: a double-blind randomised trial. J Hum Hypertens. 1998;12:135-140.
S36. Punzi H, Lewin A, Lukic T, Goodin T, Chen W. Efficacy and safety of nebivolol in
Hispanics with stage I-II hypertension: a randomized placebo-controlled trial. Ther Adv
Cardiovasc Dis. 2010 4: 349-357.
S37. Lewin A, Punzi H, Xiaohui L, Stapff M. Nebivolol monotherapy for patients with
systolic stage II hypertension: results of a randomized-placebo-controlled trial. Clin Ther.
2013;35:142–152.
S38. Neutel H, Smith D, Gradman A. Adding nebivolol to ongoing antihypertensive therapy
improves blood pressure and response rates in patients with uncontrolled stage I-II
hypertension. J Hum Hypertens. 2010;24:64-73.
S39. Giles T, Khan B, Lato J, Brener L, Ma Y, Lukic T. Nebivolol monotherapy in young
adults (younger than 55 years) with hypertension: a randomized, placebo-controlled trial. J
Clin Hypertens. 2013;15:687-693.
S40. Weiss R, Stapff M, Lin Y. Placebo effect and efficacy of nebivolol in patients with
hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebocontrolled trial. Am J Cardiovasc Drugs. 2013;13:129-140.
S41. Giles T, Weber M, Basile J, Gradman A, Bharucha D, Chen W, Pattathil M, for the
NAC-MD-01 Study Investigators. Efficacy and safety of nebivolol and valsartan as fixeddose combination in hypertension: a randomised, multicentre study. Lancet. 2014;383:188998.
S42. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P2.pdf
(11 September 2014).
S43. Chrysant S, Weber M, Wang A, Hinman D. Evaluation of antihypertensive therapy with
the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens.
2004;17:252-259.
S44. Giles T, Oparil S, Silfani T, Wang A, Walker F, on behalf of the study investigators.
Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan
in patients with essential hypertension. J Clin Hypertens. 2007;9:187–195.
S45. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P3.pdf
(11 2014).
S46. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-286_Benicar_medr_P5.pdf
(11 2014).
S47. Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan
medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a
randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
Clin Ther. 2008;30:587-604.
S48. Volpe M, Brommer P, Haag U, Miele C. Effiacy and tolerability of olmesartan
medoxomil combined with amlodipine in patients with moderate to severe hypertension after
amlodipine monotherapy. A randomized, double-blind, parallel-group, multicentre study.
Clin Drug Invest. 2009;29:11-25.
S49. Witham M, Ireland S, Houston G, Gandy S, Waugh S, MacDonald T, Mackenzie I,
Struthers A. Vitamin D therapy to reduce blood pressure and left ventricular hypertrophy in
resistant hypertension: randomized, controlled trial. Hypertens. 2014;63:706-712.
6
S50. Black H, Bakris G, Weber M, Weiss R, El Shahawy M, Marple R, Tannoury , Linas S,
Wiens B, Linseman J, Roden R, Gerber M. Efficacy and safety of darusentan in patients with
resistant hypertension: results from a randomized, double-blind, placebo-controlled doseranging study. J Clin Hypertens. 2007;9:760-769.
S51. Vaclacik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R,
Kocianova E, Taborsky M. Addition of spironolactone in patients with resistant arterial
hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.
Hypertension. 2011;57:1069-1075.
S52. Oxlund C, Henriksen J, Tarnow L, Schousboe K, Gram J, Jacobsen I. Low dose
spironolactone reduces blood pressure in patients with resistant hypertension and type 2
diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013;31:2094-2102.
S53. Bakris G, Lindholm L, Black H, Krum H, Linas S, Linseman J, Arterburn S, Sager P,
Weber M. Divergent results using clinic and ambulatory blood pressures: report of a
darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830.
S54. Weber M, Black H, Bakris G, Krum H, Linas S, Weiss R, Linseman J, Wiens B, Warren
M, Lindholm L. A selective endothelin-receptor anatagonist to reduce blood pressure in
patients with treatment-resistant hypertension: a randomised, double-blind, placebocontrolled trial. Lancet. 2009;374-1423-31.
7